Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

This study tests a new way to deliver irinotecan chemotherapy — as a mist sprayed directly inside the abdomen (intraperitoneal aerosol) — for people with extensive peritoneal carcinomatosis (cancer spread throughout the abdominal lining) from GI cancers such as pancreatic, colon, stomach, gallbladder, or appendix cancer. **You may be eligible if...** - You are 18 or older with biopsy-proven gastrointestinal cancer with extensive spread inside the abdomen - Your cancer cannot be surgically removed - Your life expectancy is more than 6 months (or more than 3 months for pancreatic cancer) - You have an adequate performance status **You may NOT be eligible if...** - You are currently receiving IV irinotecan chemotherapy - You are pregnant or breastfeeding - You are of childbearing age and unable to use effective contraception - You have a known allergy to irinotecan - You have significant amounts of ascites (fluid in the abdomen) Talk to your doctor to see if this trial is right for you.